Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 59 for “"ALK"”.

  1. ALK in the pathogenesis of cancer

    Anaplastic Lymphoma Kinase (ALK) has been implicated in the pathogenesis of many types of cancer including Anaplastic Large Cell Lymphoma (ALCL) and neuroblastoma (NB). ALK is an ideal drug target as its endogenous expression is limited to neuronal cells during neonatal development, although …

    cambridge Repository record for ALK in the pathogenesis of cancer (opens in a new tab)

  2. Modelling RANBP2-ALK-rearranged Epithelioid Inflammatory Myofibroblastic Sarcoma

    … myofibroblastic tumour characterised by ALK staining that is perinuclear or cytoplasmic with perinuclear accentuation, CD30 expression and early relapse despite crizotinib treatment [1, 2]. This study aimed to generate and utilise models of eIMS to assess molecular-targeted therapeutic …

    unsw Repository record for Modelling RANBP2-ALK-rearranged Epithelioid Inflammatory Myofibroblastic Sarcoma (opens in a new tab)

  3. Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma

    Anaplastic Lymphoma Kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a T-cell non-Hodgkin lymphoma characterised by a chromosomal rearrangement [t(2;5) (p23;q25)] involving the ALK and NPM1 genes on chromosomes 2 and 5 respectively. This translocation generates the NPM-ALK fusion …

    cambridge Repository record for Novel treatment strategy for ALK-positive Anaplastic Large Cell Lymphoma (opens in a new tab)

  4. Multilevel Deregulation of Survival Mechanisms In Npm-Alk+ T-Cell Lymphoma

    <p>The anaplastic lymphoma kinase (ALK) is a single chain transmembrane receptor tyrosine kinase that belongs to the insulin receptor superfamily. Other members of this superfamily include the insulin receptor (IR), type I insulin-like growth factor receptor (IGF-IR), and the leukocyte tyrosine …

    uthsc Repository record for Multilevel Deregulation of Survival Mechanisms In Npm-Alk+ T-Cell Lymphoma (opens in a new tab)

  5. Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK

    Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in the development of the gut and nervous system, initially cloned from cases of T-cell lymphoma. ALK has been frequently implicated in diverse cancers through oncogenic translocations, mutations, chromosomal inversion, or amplification …

    cambridge Repository record for Studying the Transcriptional and Epigenetic Perturbations of Haematopathologies Expressing NPM1-ALK (opens in a new tab)

  6. FUNCTIONAL ANALYSIS OF ANAPLASTIC LYMPHOMA KINASE DURING EMBRYONIC NEUROGENESIS IN ZEBRAFISH

    … tyrosine kinase gene Anaplastic Lymphoma Kinase (ALK) was initially discovered as an oncogene. ALK kinase over-activation has been associated with human cancers, most importantly neuroblastoma. However, little is known about ALK¿s endogenous function in development. I identified an alk ortholog in …

    nus Repository record for FUNCTIONAL ANALYSIS OF ANAPLASTIC LYMPHOMA KINASE DURING EMBRYONIC NEUROGENESIS IN ZEBRAFISH (opens in a new tab)

  7. Identificación de reordenamientos y expresión proteica de ALK en tejido tumoral de pacientes con adenocarcinoma de pulmón

    El gen ALK está situado en el brazo corto del cromosoma 2p23 y codifica una proteína con función de receptor denominada linfoma quinasa anaplásica. La prevalencia de reordenamientos en ALK para el cáncer de pulmón de células no pequeñas (NSCLC) corresponde a un 1-13%. Los reordenamientos en el gen …

    javeriana Repository record for Identificación de reordenamientos y expresión proteica de ALK en tejido tumoral de pacientes con adenocarcinoma de pulmón (opens in a new tab)

  8. NOVEL THERAPEUTIC STRATEGIES IN LUNG CANCERSTRONG BIOLOGICAL BIAS FOR ALK INTRON 19 BREAKPOINTS IN NON-SMALL LUNG CANCER

    … therapy with tyrosine kinase inhibitors. EML4-ALK translocations are detected in 4-8 % of NSCLC and define a specific subtype of oncogene-driven lung cancer. While different EML4-ALK variants are defined by different breakpoints in the EML4 gene, most frequently located in intron 6 or 13, ALK

    catania Repository record for NOVEL THERAPEUTIC STRATEGIES IN LUNG CANCERSTRONG BIOLOGICAL BIAS FOR ALK INTRON 19 BREAKPOINTS IN NON-SMALL LUNG CANCER (opens in a new tab)

  9. Searching for the missing T Cell Receptor (TCR) in Anaplastic Large Cell Lymphoma (ALCL): Surplus to requirements or a protagonist in lymphomagenesis?

    … entities: ALCL, Anaplastic Lymphoma Kinase (ALK)+, ALCL ALK- and cutaneous ALCL. In the majority of ALCL, ALK+, ALK is expressed as the result of a chromosomal translocation generating Nucleophosmin 1(NPM)-ALK, which is considered the main driver. ALCL have an unusual immunophenotype; they …

    cambridge Repository record for Searching for the missing T Cell Receptor (TCR) in Anaplastic Large Cell Lymphoma (ALCL): Surplus to requirements or a protagonist in lymphomagenesis? (opens in a new tab)

  10. Functional identification of molecular oncotargets associated with the resistance to ALK inhibition in neuroblastoma via genome-wide CRISPR-Cas9 screens

    … have identified Anaplastic Lymphoma Kinase (ALK) as the only directly ‘druggable’ target with a significant mutation rate (9%). ALK is a receptor tyrosine kinase whose dysregulation has been implicated as the driver lesion in a variety of cancer types, including Non-Small Cell Lung Cancer …

    cambridge Repository record for Functional identification of molecular oncotargets associated with the resistance to ALK inhibition in neuroblastoma via genome-wide CRISPR-Cas9 screens (opens in a new tab)

  11. Investigating the genome of Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma

    … hyperactivation of Anaplastic Lymphoma Kinase (ALK) as the consequence of a chromosomal translocation. Patients diagnosed with ALCL are still treated with toxic multi-agent chemotherapy and as many as 25-50% of patients relapse. It is clear that continued adaption of current therapies will …

    cambridge Repository record for Investigating the genome of Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma (opens in a new tab)

  12. Cost-utility analysis of EML4-ALK fusion testing followed by treatment with crizotinib in patients with Non-Small Cell Lung Cancer (NSCLC)

    … by Pfizer, Inc. demonstrated that crizotinib (Xalkori, Pfizer, Inc.) offers significant improvement in clinical outcomes as a second line therapy for the treatment of EML4-ALK fusion–positive non-small-cell lung cancer (NSCLC). In 2013, the US Food and Drug Administration (FDA) approved …

    washington Repository record for Cost-utility analysis of EML4-ALK fusion testing followed by treatment with crizotinib in patients with Non-Small Cell Lung Cancer (NSCLC) (opens in a new tab)

  13. Dissecting mechanisms and consequences of oncogenic RTK fusion signaling

    … and live-cell imaging to find that EML4-ALK, an oncogenic fusion present in 5-7% of non-small cell lung cancers, suppress transmembrane RTK signaling by sequestering RTK adapter proteins including GRB2 and SOS1. Furthermore, ALK inhibition, while suppressing oncogenic signaling, …

    penn Repository record for Dissecting mechanisms and consequences of oncogenic RTK fusion signaling (opens in a new tab)

  14. APPLICATION OF STRUCTURAL, MOLECULAR, AND PROTOEMIC STUDIES TO INVESTIGATE ON-TARGET AND OFF-TARGET MECHANISMS OF LORLATINIB RESISTANCE IN ALK DRIVEN NEUROBLASTOMA

    … and discovery of anaplastic lymphoma kinase (ALK) receptor activating mutations and amplification has provided hope to further increase of patient survival. Despite this success and that of precision medicine at large, patients treated with ALK inhibitor lorlatinib have developed resistance, a …

    penn Repository record for APPLICATION OF STRUCTURAL, MOLECULAR, AND PROTOEMIC STUDIES TO INVESTIGATE ON-TARGET AND OFF-TARGET MECHANISMS OF LORLATINIB RESISTANCE IN ALK DRIVEN NEUROBLASTOMA (opens in a new tab)

  15. Characterization of an alkalophilic Bacillus brevis isolate with respect to its endo-(1,3-1,4)-β-glucanase gene, protein hyperproduction and the degS-degU operon

    Bacillus brevis Alk 36 was isolated from soil during a screening programme for the selection of extracellular enzyme producing strains. A gene coding for an endo(1,3- 1,4 )-.8-glucanase (or lichenase) was cloned from B. brevis Alk 36 and expressed in Escherichia coli. The nucleotide sequence of …

    cape-town Repository record for Characterization of an alkalophilic Bacillus brevis isolate with respect to its endo-(1,3-1,4)-β-glucanase gene, protein hyperproduction and the degS-degU operon (opens in a new tab)

Page 1 of 3